Early Development of Vaccines Against Infectious Diseases – DCAI (89)

Topics

• Identification and initial characterization of potential vaccine targets for early- and mid-stage vaccine development (inactivated vaccines, live-attenuated vaccines, mRNA vaccines, toxoid vaccines, viral vector vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines)
• Vaccines against pathogens of clinical or veterinary interest, including bacteria, viruses (except HIV), parasites, fungi, bacterial toxins, and pathogenic agents that have biodefense implications
• Immune mechanism, vaccine-induced immune response, immune profile, and identification of molecular mechanism.
• Development and immunologic evaluation of the adjuvant systems
• Cloning and development of vector systems

Shared Interests and Overlaps

There are shared interests with Vaccines against Infectious Diseases (VID).. Applications that emphasize late-stage development and measure vaccine efficacy, safety, or improvement may be reviewed in VID. Applications that emphasize early to mid-stage development of vaccines may be reviewed in DCAI (89).

There are shared interests in immune responses to pathogens with Immunity and Host Defense (IHD). Applications that emphasize basic immunological studies, such as mechanistic studies of the innate, systemic, and mucosal immune responses to microbial organisms may be reviewed by IHD. Applications that emphasize the generation of vaccines may be reviewed in DCAI (89).

There are shared interests with Innovations in Nanosystems and Nanotechnology (INN) in developing novel vaccine nanomaterials. Applications that emphasize the design, synthesis, and development of nanomaterials may be reviewed in INN. Applications that emphasize the use of existing nanomaterials in a vaccine may be reviewed in DCAI (89).

There are shared interests in nucleic acid-based vaccine development with Drug and Biologic Therapeutic Delivery (DBTD) and Nucleic Acid Therapeutic Delivery [BBBT (81)]. Applications that emphasize novel methods for vaccine delivery, with a focus on bioengineering principles, may be reviewed in DBTD or BBBT (81). Applications that emphasize vaccine immune responses may be reviewed in DCAI (89).

There are shared interests with Immunobiology of Transplantation and Alloimmunity (ITA). Applications that focus on the impact of immunosuppressive therapies on immune responses to vaccine and/or vaccine performance may be reviewed in ITA. Applications that focus on general approaches to understand immune responses to vaccines, may be reviewed in DCAI (89).